NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.
Publication
, Journal Article
Clark, PE; Spiess, PE; Agarwal, N; Bangs, R; Boorjian, SA; Buyyounouski, MK; Efstathiou, JA; Flaig, TW; Friedlander, T; Greenberg, RE; Guru, KA ...
Published in: J Natl Compr Canc Netw
October 2016
These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
October 2016
Volume
14
Issue
10
Start / End Page
1213 / 1224
Location
United States
Related Subject Headings
- Urinary Bladder Neoplasms
- Oncology & Carcinogenesis
- Humans
- Antineoplastic Agents
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Clark, P. E., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., … Smith, C. (2016). NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw, 14(10), 1213–1224. https://doi.org/10.6004/jnccn.2016.0131
Clark, Peter E., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, et al. “NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.” J Natl Compr Canc Netw 14, no. 10 (October 2016): 1213–24. https://doi.org/10.6004/jnccn.2016.0131.
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct;14(10):1213–24.
Clark, Peter E., et al. “NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.” J Natl Compr Canc Netw, vol. 14, no. 10, Oct. 2016, pp. 1213–24. Pubmed, doi:10.6004/jnccn.2016.0131.
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct;14(10):1213–1224.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
October 2016
Volume
14
Issue
10
Start / End Page
1213 / 1224
Location
United States
Related Subject Headings
- Urinary Bladder Neoplasms
- Oncology & Carcinogenesis
- Humans
- Antineoplastic Agents
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis